메뉴 건너뛰기




Volumn 5, Issue 11, 2017, Pages 887-897

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

(373)  Vaccaro, Olga a   Masulli, Maria a   Nicolucci, Antonio b   Bonora, Enzo c   Del Prato, Stefano d   Maggioni, Aldo P e   Rivellese, Angela A a   Squatrito, Sebastiano f   Giorda, Carlo B g   Sesti, Giorgio h   Mocarelli, Paolo i   Lucisano, Giuseppe b   Sacco, Michele b   Signorini, Stefano i   Cappellini, Fabrizio i   Perriello, Gabriele j   Babini, Anna Carla k,at   Lapolla, Annunziata l   Gregori, Giovanna m,at   Giordano, Carla n   more..


Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

EID: 85029216639     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30317-0     Document Type: Article
Times cited : (234)

References (30)
  • 1
    • 3142680168 scopus 로고    scopus 로고
    • Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial
    • Vaccaro, O, Eberly, LE, Neaton, JD, Yang, L, Riccardi, G, Stamler, J, for the Multiple Risk Factor Intervention Trial (MRFIT) Research Group. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med 164 (2004), 1438–1443.
    • (2004) Arch Intern Med , vol.164 , pp. 1438-1443
    • Vaccaro, O.1    Eberly, L.E.2    Neaton, J.D.3    Yang, L.4    Riccardi, G.5    Stamler, J.6
  • 2
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 4
    • 0032983666 scopus 로고    scopus 로고
    • Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)
    • Turner, RC, Cull, CA, Frighi, V, Holman, RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999), 2005–2012.
    • (1999) JAMA , vol.281 , pp. 2005-2012
    • Turner, R.C.1    Cull, C.A.2    Frighi, V.3    Holman, R.R.4
  • 5
    • 84925489733 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Inzucchi, SE, Bergenstal, RM, Buse, JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
    • (2015) Diabetologia , vol.58 , pp. 429-442
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 6
    • 33750469241 scopus 로고    scopus 로고
    • Standards of medical care in diabetes—2017
    • American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care 40:suppl 1 (2017), S1–S135.
    • (2017) Diabetes Care , vol.40 , pp. S1-S135
  • 7
    • 85019196764 scopus 로고    scopus 로고
    • Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013
    • Lipska, KJ, Yao, X, Herrin, J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 40 (2017), 468–475.
    • (2017) Diabetes Care , vol.40 , pp. 468-475
    • Lipska, K.J.1    Yao, X.2    Herrin, J.3
  • 8
    • 84978976076 scopus 로고    scopus 로고
    • Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis
    • Palmer, SC, Mavridis, D, Nicolucci, A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
    • (2016) JAMA , vol.316 , pp. 313-324
    • Palmer, S.C.1    Mavridis, D.2    Nicolucci, A.3
  • 9
    • 84928429195 scopus 로고    scopus 로고
    • Cardiovascular safety of sulphonylureas: over 40  years of continuous controversy without an answer
    • Abdelmoneim, AS, Eurich, DT, Light, PE, et al. Cardiovascular safety of sulphonylureas: over 40  years of continuous controversy without an answer. Diabetes Obes Metab 17 (2015), 523–532.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 523-532
    • Abdelmoneim, A.S.1    Eurich, D.T.2    Light, P.E.3
  • 10
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    • Dormandy, JA, Charbonnel, B, Eckland, DJA, et al., on behalf of the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.A.3
  • 11
    • 84962114446 scopus 로고    scopus 로고
    • Pioglitazone after ischemic stroke or transient ischemic attack
    • Kernan, WN, Viscoli, CM, Furie, LH, et al., for the IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
    • (2016) N Engl J Med , vol.374 , pp. 1321-1331
    • Kernan, W.N.1    Viscoli, C.M.2    Furie, L.H.3
  • 12
    • 84938364689 scopus 로고    scopus 로고
    • Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes
    • Lewis, JD, Habel, LA, Quesenberry, CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314 (2015), 265–277.
    • (2015) JAMA , vol.314 , pp. 265-277
    • Lewis, J.D.1    Habel, L.A.2    Quesenberry, C.P.3
  • 13
    • 84908564226 scopus 로고    scopus 로고
    • Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials
    • Zhu, NZ, Jang, YF, Ding, T, Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68 (2014), 115–123.
    • (2014) Bone , vol.68 , pp. 115-123
    • Zhu, N.Z.1    Jang, Y.F.2    Ding, T.3
  • 14
    • 84928803853 scopus 로고    scopus 로고
    • The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies
    • Lorenzo, CV, Margulis, A, Pladevall, M, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord, 14, 2014, 129.
    • (2014) BMC Cardiovasc Disord , vol.14 , pp. 129
    • Lorenzo, C.V.1    Margulis, A.2    Pladevall, M.3
  • 15
    • 85020727559 scopus 로고    scopus 로고
    • Revisiting the use of pioglitazone in the treatment of type 2 diabetes
    • Einhorn, D, Fonseca, V, Revisiting the use of pioglitazone in the treatment of type 2 diabetes. Endocr Pract 22 (2016), 1343–1346.
    • (2016) Endocr Pract , vol.22 , pp. 1343-1346
    • Einhorn, D.1    Fonseca, V.2
  • 16
    • 84868367261 scopus 로고    scopus 로고
    • Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial
    • Vaccaro, O, Masulli, M, Bonora, E, et al., On behalf of the TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis 22 (2012), 997–1006.
    • (2012) Nutr Metab Cardiovasc Dis , vol.22 , pp. 997-1006
    • Vaccaro, O.1    Masulli, M.2    Bonora, E.3
  • 17
    • 85045679671 scopus 로고    scopus 로고
    • Associazione Medici Diabetologi (AMD), Società Italiana di Diabetologia (SID). Standard Italiani per la cura del diabete mellito, 2016, Edizioni Infomedica, Torino.
  • 18
    • 85045617699 scopus 로고    scopus 로고
    • European Medicines Agency. European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increased risk of bladder cancer. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf, July 21, 2011 (accessed March 30, 2017).
  • 19
    • 25444474448 scopus 로고    scopus 로고
    • A review of methods for futility stopping based on conditional power
    • Lachin, JM, A review of methods for futility stopping based on conditional power. Stat Med 24 (2005), 2747–2764.
    • (2005) Stat Med , vol.24 , pp. 2747-2764
    • Lachin, J.M.1
  • 20
    • 84921350530 scopus 로고    scopus 로고
    • Singer, JD, Willett, JB, Applied longitudinal data analysis: modeling change and event occurrence, 2003, Oxford University Press, New York.
  • 21
    • 84946049571 scopus 로고    scopus 로고
    • Excess mortality in persons with type 2 diabetes
    • Tancredi, M, Rosengren, A, Svenson, A-M, et al. Excess mortality in persons with type 2 diabetes. N Engl J Med 373 (2015), 1720–1732.
    • (2015) N Engl J Med , vol.373 , pp. 1720-1732
    • Tancredi, M.1    Rosengren, A.2    Svenson, A.-M.3
  • 22
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
    • (1998) Lancet , vol.352 , pp. 854-865
  • 23
    • 67149146438 scopus 로고    scopus 로고
    • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    • Home, PD, Pocock, SJ, Beck-Nielsen, H, et al., for the RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
    • (2009) Lancet , vol.373 , pp. 2125-2135
    • Home, P.D.1    Pocock, S.J.2    Beck-Nielsen, H.3
  • 24
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
    • (2008) N Engl J Med , vol.358 , pp. 2560-2572
  • 26
    • 41649084422 scopus 로고    scopus 로고
    • Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial
    • Nissen, SE, Nicholls, SJ, Wolski, K, et al., for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008), 1561–1573.
    • (2008) JAMA , vol.299 , pp. 1561-1573
    • Nissen, S.E.1    Nicholls, S.J.2    Wolski, K.3
  • 27
    • 84855512299 scopus 로고    scopus 로고
    • Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes
    • Sam, S, Haffner, S, Davidson, MH, D'Agostino, R Sr, Perez, A, Mazzone, T, Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J Clin Endocrinol Metab 97 (2012), E110–E114.
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. E110-E114
    • Sam, S.1    Haffner, S.2    Davidson, M.H.3    D'Agostino, R.4    Perez, A.5    Mazzone, T.6
  • 28
    • 33845405222 scopus 로고    scopus 로고
    • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
    • Kahn, SE, Haffner, SM, Heise, MA, et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 335 (2006), 2427–2443.
    • (2006) N Engl J Med , vol.335 , pp. 2427-2443
    • Kahn, S.E.1    Haffner, S.M.2    Heise, M.A.3
  • 29
    • 84901768284 scopus 로고    scopus 로고
    • Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    • Holman, RR, Sourij, H, Califf, RM, Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017.
    • (2014) Lancet , vol.383 , pp. 2008-2017
    • Holman, R.R.1    Sourij, H.2    Califf, R.M.3
  • 30
    • 84926475145 scopus 로고    scopus 로고
    • Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA)
    • Marx, N, Rosenstock, J, Kahn, SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA). Diab Vasc Dis Res 12 (2015), 164–174.
    • (2015) Diab Vasc Dis Res , vol.12 , pp. 164-174
    • Marx, N.1    Rosenstock, J.2    Kahn, S.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.